A risk-benefit assessment of anti-obesity drugs (Q33542534)

27 July 2017

1 reference

title

A risk-benefit assessment of anti-obesity drugs (English)

1 reference

27 July 2017

0 references

J Kolanowski

1

1 reference

27 July 2017

1 February 1999

1 reference

27 July 2017

1 reference

27 July 2017

20

1 reference

27 July 2017

2

1 reference

27 July 2017

119-131

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199920020-00003

27 July 2017

0 references

cites work

Pharmacological and clinical studies of ephedrine and other thermogenic agonists

1 reference

12 December 2020

A double-blind randomized placebo-controlled trial of sibutramine

1 reference

12 December 2020

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

1 reference

12 December 2020

Benefit:risk consideration in long-term therapy with dexfenfluramine

1 reference

12 December 2020

A one-year trial to assess the value of orlistat in the management of obesity

1 reference

12 December 2020

Long-term weight loss: the effect of pharmacologic agents

1 reference

12 December 2020

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine

1 reference

12 December 2020

The NAASO position paper on approval and use of drugs to treat obesity

1 reference

12 December 2020

Sibutramine--a review of clinical efficacy

1 reference

12 December 2020

Time trends in obesity: an epidemiological perspective

1 reference

12 December 2020

The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial

1 reference

12 December 2020

A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination

1 reference

12 December 2020

Pharmacological aspects of obesity treatment: towards the 21st century

1 reference

12 December 2020

Combined drug treatment of obesity

1 reference

12 December 2020

Overview of adrenergic anorectic agents

1 reference

12 December 2020

Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.

1 reference

12 December 2020

Actual causes of death in the United States

1 reference

12 December 2020

Clinical studies with phenylpropanolamine: a metaanalysis

1 reference

12 December 2020

Use and abuse of appetite-suppressant drugs in the treatment of obesity

1 reference

12 December 2020

The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial

1 reference

12 December 2020

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

12 December 2020

Lipase inhibition: a novel concept in the treatment of obesity

1 reference

12 December 2020

Sibutramine reduces food intake in non-dieting women with obesity

1 reference

12 December 2020

Phenylpropanolamine and blood pressure: a review of prospective studies

1 reference

12 December 2020

Sibutramine: a review of the pharmacology of a novel anti-obesity agent

1 reference

12 December 2020

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity

1 reference

12 December 2020

Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.

1 reference

12 December 2020

Fluoxetine's effect on weight loss in obese subjects

1 reference

12 December 2020

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

12 December 2020

Mode of action of orlistat

1 reference

12 December 2020

Long-term drug treatment of obesity in a private practice setting

1 reference

12 December 2020

THE LONG-TERM MANAGEMENT OF OBESITY IN GENERAL PRACTICE

1 reference

12 December 2020

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

12 December 2020

Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success

1 reference

12 December 2020

Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients

1 reference

12 December 2020

Clinical studies with dexfenfluramine: from past to future

1 reference

12 December 2020

Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

1 reference

12 December 2020

Prolonged use of a very low calorie diet (Cambridge diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine

1 reference

12 December 2020

Increased plasma serotonin in primary pulmonary hypertension

1 reference

12 December 2020

Valvular heart disease associated with fenfluramine-phentermine

1 reference

12 December 2020

Clinical studies with mazindol

1 reference

12 December 2020

International trial of long-term dexfenfluramine in obesity.

1 reference

12 December 2020

Aminorex and pulmonary hypertension. A review.

1 reference

12 December 2020

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

12 December 2020

Evaluation of drugs for treating obesity

1 reference

12 December 2020

Appraisal of the clinical value of serotoninergic drugs

1 reference

12 December 2020

Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.

1 reference

12 December 2020

Comparison of continuous and intermittent anorectic therapy in obesity.

1 reference

12 December 2020

Guidelines for the approval and use of drugs to treat obesity. A position paper of The North American Association for the Study of Obesity

1 reference

12 December 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

12 December 2020

Pharmacotherapy for obesity -- do the benefits outweigh the risks?

1 reference

12 December 2020

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

12 December 2020

The serotonin syndrome. Implicated drugs, pathophysiology and management

1 reference

12 December 2020

Effectiveness of phenylpropanolamine in the management of moderate obesity

1 reference

12 December 2020

The fen-phen finale: a study of weight loss and valvular heart disease

1 reference

12 December 2020

Effects of sibutramine on resting metabolic rate and weight loss in overweight women

1 reference

12 December 2020

Valvular heart disease associated with dexfenfluramine

1 reference

12 December 2020

Further cases of valvular heart disease associated with fenfluramine-phentermine

1 reference

12 December 2020

Long-term use of diethylpropion in obesity

1 reference

12 December 2020

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

12 December 2020

10.2165/00002018-199920020-00003

Identifiers

DOI

1 reference

PubMed ID

10082070

Dimensions Publication ID

27 July 2017

0 references

1 reference

PubMed ID

10082070